Program
GPC3-targeted Plasmid DNA Vaccine NWRD06
Also written as “NWRD06 administered by electroporation”, “1mg NWRD06 administered by electroporation” and “4mg NWRD06 administered by electroporation”.
Its studies are mostly in Carcinoma, Hepatocellular, led by Newish Biotech (Wuxi).
Furthest: phase 2, since Dec 23, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Newish Biotech (Wuxi) | 22 open or running | phase 2since Dec 23, 2025 | Sep 27, 2023 | Dec 31, 2028phase 2 · NCT07324304 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2023First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT06088459 · 9 planned · China
- Dec 23, 2025Phase 2 study in Carcinoma, HepatocellularPhase 2 reachedNCT07324304 · 30 planned · China
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07324304
TargetBeta
GPC3 →read by rule
“A plasmid DNA therapeutic cancer vaccine encoding glypican-3 (GPC3), ”NCIt, by rule
Other programs on GPC3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 3 |
| codrituzumab | Hoffmann-La Roche | phase 2 | 3 |
| Actinium Ac 225 GPC3-targeted Peptide RYZ801 | Bristol-Myers Squibb | phase 2 | 1 |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ZW251rule | Zymeworks | phase 1 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ABBV-324 | AbbVie | phase 1 | 1 |
| Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926rule | Bayer | phase 1 | 1 |
| ACE723rule | acepodia-biotech-inc | phase 1 | 1 |
| TQB6426rule | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07324304Carcinoma, Hepatocellular · China | 2 | Recruiting | Dec 31, 2028 | 30 |
| NCT06088459Carcinoma, Hepatocellular · China | 1 | Recruiting | Dec 2024 | 9 |
How it is read
Names in the registry
- “NWRD06 administered by electroporation”, 1 entry
- “1mg NWRD06 administered by electroporation”, 1 entry
- “4mg NWRD06 administered by electroporation”, 1 entry
- “8mg NWRD06 administered by electroporation”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.